Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Programmed Cell Death 1 Receptor"" wg kryterium: Temat


Tytuł :
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Autorzy :
Kong X; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Lu P; State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Liu C; Department of Pharmaceutical Analysis, School of Chinese Materia Medical, Beijing University of Chinese Medicine, Beijing 102488, P.R. China.
Guo Y; Department of Radiotherapy, Tianjin Hospital, Tianjin 300211, P.R. China.
Yang Y; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Peng Y; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Wang F; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Bo Z; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Dou X; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Shi H; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Meng J; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Pokaż więcej
Źródło :
Molecular medicine reports [Mol Med Rep] 2021 May; Vol. 23 (5). Date of Electronic Publication: 2021 Mar 24.
Typ publikacji :
Journal Article; Review
MeSH Terms :
B7-H1 Antigen/*genetics
Immune Checkpoint Inhibitors/*therapeutic use
Neoplasms/*therapy
Programmed Cell Death 1 Receptor/*genetics
B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Humans ; Immune Checkpoint Inhibitors/immunology ; Immunotherapy/trends ; Neoplasms/genetics ; Neoplasms/immunology ; Oncolytic Virotherapy/trends ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology
Czasopismo naukowe
Tytuł :
Transcriptional and epigenetic regulation of PD-1 expression.
Autorzy :
Chi Z; Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, China.
Lu Y; Institute of Basic Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, China.; Science and Technology Innovation Center, Shandong First Medical University, Jinan, 250014, China.
Yang Y; Key Laboratory of Rare and Uncommon Diseases, Department of Microbiology, Institute of Basic Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250062, China.
Li B; Institute of Basic Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, China.
Lu P; Institute of Basic Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, China. .; Science and Technology Innovation Center, Shandong First Medical University, Jinan, 250014, China. .
Pokaż więcej
Źródło :
Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2021 Apr; Vol. 78 (7), pp. 3239-3246. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Autoimmunity*
Epigenesis, Genetic*
Gene Expression Regulation*
Programmed Cell Death 1 Receptor/*metabolism
Animals ; Humans ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/immunology ; Signal Transduction
Czasopismo naukowe
Tytuł :
Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.
Autorzy :
Yu M; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Peng Z; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Qin M; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Liu Y; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Wang J; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Zhang C; Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Lin J; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Dong T; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Wang L; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Li S; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Yang Y; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Xu S; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Guo W; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Zhang X; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Shi M; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Peng H; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Luo X; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Zhang H; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Zhang L; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, China.
Li Y; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Yang XP; Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Sun S; Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2021 Mar 18; Vol. 81 (6), pp. 1216-1230.e9. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Immunotherapy*
Neoplasms, Experimental*/genetics
Neoplasms, Experimental*/metabolism
Neoplasms, Experimental*/pathology
Neoplasms, Experimental*/therapy
Adaptor Proteins, Signal Transducing/*metabolism
Immune Checkpoint Inhibitors/*pharmacology
Interferon-gamma/*metabolism
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Transcription Factors/*metabolism
A549 Cells ; Adaptor Proteins, Signal Transducing/genetics ; Animals ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; HEK293 Cells ; Humans ; Interferon-gamma/genetics ; Mice ; Mice, Knockout ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/metabolism ; Transcription Factors/genetics
Czasopismo naukowe
Tytuł :
MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
Autorzy :
Dusenbery AC; University of Virginia Department of Pathology.
Maniaci JL; University of Virginia School of Medicine, Charlottesville, VA.
Hillerson ND; University of Virginia School of Medicine, Charlottesville, VA.
Dill EA; University of Virginia Department of Pathology.
Bullock TN; University of Virginia Department of Pathology.
Mills AM; University of Virginia Department of Pathology.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2021 May 01; Vol. 45 (5), pp. 701-707.
Typ publikacji :
Journal Article
MeSH Terms :
B7-H1 Antigen/*analysis
Biomarkers, Tumor/*analysis
Histocompatibility Antigens Class I/*analysis
Programmed Cell Death 1 Receptor/*analysis
Triple Negative Breast Neoplasms/*immunology
Adaptive Immunity ; Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/antagonists & inhibitors ; Biomarkers, Tumor/antagonists & inhibitors ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunohistochemistry ; Middle Aged ; Patient Selection ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Tissue Array Analysis ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Autorzy :
Singh L; Department of Ocular Pathology, Dr. R P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.; Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, USA.; Biosciences, Jamia Millia Islamia, New Delhi, India.
Singh MK; Department of Ocular Pathology, Dr. R P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Kenney MC; Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, USA.
Jager MJ; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Rizvi MA; Biosciences, Jamia Millia Islamia, New Delhi, India.
Meel R; Department of Ophthalmology, Dr. R. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Lomi N; Department of Ophthalmology, Dr. R. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Bakhshi S; Department of Medical Oncology, All India Institute of Medical Sciences, IRCH, New Delhi, India.
Sen S; Department of Ocular Pathology, Dr. R P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Kashyap S; Department of Ocular Pathology, Dr. R P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 May; Vol. 70 (5), pp. 1291-1303. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Journal Article
MeSH Terms :
B7-H1 Antigen/*metabolism
Eye Neoplasms/*metabolism
Immunotherapy/*methods
Lymphocytes, Tumor-Infiltrating/*immunology
Melanoma/*metabolism
Programmed Cell Death 1 Receptor/*metabolism
Uveal Neoplasms/*metabolism
B7-H1 Antigen/genetics ; Cell Line, Tumor ; Cell Movement ; Eye Neoplasms/diagnosis ; Eye Neoplasms/mortality ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Interferon-gamma/metabolism ; Melanoma/diagnosis ; Melanoma/mortality ; Polymerase Chain Reaction ; Prognosis ; Programmed Cell Death 1 Receptor/genetics ; Survival Analysis ; Uveal Neoplasms/diagnosis ; Uveal Neoplasms/mortality
SCR Disease Name :
Uveal melanoma
Czasopismo naukowe
Tytuł :
Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis.
Autorzy :
Davis RJ; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Lina I; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Ding D; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Engle EL; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, U.S.A.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Taube J; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, U.S.A.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Gelbard A; Department of Otolaryngology, Vanderbilt University School of Medicine, Nashville, TN, U.S.A.
Hillel AT; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Pokaż więcej
Źródło :
The Laryngoscope [Laryngoscope] 2021 May; Vol. 131 (5), pp. 967-974. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji :
Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
B7-H1 Antigen/*metabolism
Laryngostenosis/*immunology
Programmed Cell Death 1 Receptor/*metabolism
Tracheal Stenosis/*immunology
B7-H1 Antigen/analysis ; Biopsy ; Case-Control Studies ; Cells, Cultured ; Cricoid Cartilage/immunology ; Cricoid Cartilage/pathology ; Cricoid Cartilage/surgery ; Female ; Fibroblasts ; Fibrosis ; Humans ; Immunohistochemistry ; Laryngostenosis/pathology ; Laryngostenosis/surgery ; Male ; Middle Aged ; Primary Cell Culture ; Programmed Cell Death 1 Receptor/analysis ; Trachea/immunology ; Trachea/pathology ; Trachea/surgery ; Tracheal Stenosis/pathology ; Tracheal Stenosis/surgery ; Tracheostomy
Czasopismo naukowe
Tytuł :
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Autorzy :
Wang Z; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Goto Y; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Allevato MM; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Wu VH; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Saddawi-Konefka R; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. .; Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, CA, USA. .
Gilardi M; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Alvarado D; Celldex Therapeutics, Hampton, NJ, USA.
Yung BS; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
O'Farrell A; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Molinolo AA; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Duvvuri U; Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Grandis JR; Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA.
Califano JA; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.; Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, CA, USA.
Cohen EEW; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Gutkind JS; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. .; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Apr 22; Vol. 12 (1), pp. 2383. Date of Electronic Publication: 2021 Apr 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Head and Neck Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Receptor, ErbB-3/*antagonists & inhibitors
Squamous Cell Carcinoma of Head and Neck/*drug therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Female ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/immunology ; Head and Neck Neoplasms/pathology ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Mice ; Mutation ; Precision Medicine/methods ; Programmed Cell Death 1 Receptor/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Receptor, ErbB-3/metabolism ; Signal Transduction/drug effects ; Signal Transduction/genetics ; Squamous Cell Carcinoma of Head and Neck/genetics ; Squamous Cell Carcinoma of Head and Neck/immunology ; Squamous Cell Carcinoma of Head and Neck/pathology ; TOR Serine-Threonine Kinases/metabolism ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
Autorzy :
Peng S; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Tan M; Department of Otolaryngology, The Johns Hopkins University, Baltimore, MD, USA.
Li YD; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Cheng MA; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Farmer E; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Ferrall L; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Gaillard S; Oncology, The Johns Hopkins University, Baltimore, MD, USA.; Obstetrics and Gynecology, The Johns Hopkins University, Baltimore, MD, USA.
Roden RBS; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.; Oncology, The Johns Hopkins University, Baltimore, MD, USA.
Hung CF; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA.; Oncology, The Johns Hopkins University, Baltimore, MD, USA.; Obstetrics and Gynecology, The Johns Hopkins University, Baltimore, MD, USA.
Wu TC; Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA. .; Oncology, The Johns Hopkins University, Baltimore, MD, USA. .; Obstetrics and Gynecology, The Johns Hopkins University, Baltimore, MD, USA. .; Molecular Microbiology and Immunology, The Johns Hopkins University, Baltimore, MD, USA. .; Johns Hopkins School of Medicine, 1550 Orleans St, CRB II - Room 309, Baltimore, MD, 21287, USA. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Apr; Vol. 70 (4), pp. 1049-1062. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*pharmacology
Cancer Vaccines/*administration & dosage
Immunity, Cellular/*immunology
Papillomavirus E7 Proteins/*administration & dosage
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Recombinant Fusion Proteins/*administration & dosage
Uterine Cervical Neoplasms/*prevention & control
Animals ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; Cancer Vaccines/immunology ; Female ; Immunity, Cellular/drug effects ; Lymphocytes, Tumor-Infiltrating/drug effects ; Lymphocytes, Tumor-Infiltrating/immunology ; Mice ; Mice, Inbred C57BL ; Papillomavirus E7 Proteins/genetics ; Papillomavirus E7 Proteins/immunology ; Programmed Cell Death 1 Receptor/immunology ; Recombinant Fusion Proteins/immunology ; Uterine Cervical Neoplasms/immunology ; Uterine Cervical Neoplasms/metabolism ; Vaccination
Czasopismo naukowe
Tytuł :
Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Autorzy :
Kushlinskii NE; N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of the Russian Federation.; A.I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Health of the Russian Federation.
Gershtein ES; N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of the Russian Federation.; A.I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Health of the Russian Federation.
Chang VL; Medical Institute of G.R. Derzhavin Tambov State University of the Ministry of Science and Higher Education of the Russian Federation.
Korotkova EA; N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of the Russian Federation.
Alferov AA; N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of the Russian Federation.; A.I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Health of the Russian Federation.
Kontorshchikov MM; Privolzhsky Research Medical University.
Sokolov NY; N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of the Russian Federation.
Karamysheva EI; A.I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Health of the Russian Federation.
Ognerubov NA; Medical Institute of G.R. Derzhavin Tambov State University of the Ministry of Science and Higher Education of the Russian Federation.
Stilidi IS; N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of the Russian Federation.
Pokaż więcej
Transliterated Title :
Прогностическая значимость растворимых форм рецептора и лиганда контрольной точки иммунитета PD-1/PD-L1 в плазме крови больных раком желудка.
Źródło :
Klinicheskaia laboratornaia diagnostika [Klin Lab Diagn] 2021 Mar 30; Vol. 66 (3), pp. 139-146.
Typ publikacji :
Journal Article
MeSH Terms :
Programmed Cell Death 1 Receptor*
Stomach Neoplasms*
Biomarkers, Tumor ; Humans ; Ligands ; Plasma ; Prognosis
Czasopismo naukowe
Tytuł :
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Autorzy :
Mulder EEAP; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.; Department of Surgical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
de Joode K; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
Litière S; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht Cancer Centre, Utrecht, The Netherlands.
Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
de Groot JWB; Department of Medical Oncology, Isala Oncological Centre, Zwolle, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Amsterdam University Medical Centre - location VU, Amsterdam, The Netherlands.
Aarts MJB; Department of Medical Oncology, Maastricht University Medical Centre +, Maastricht, The Netherlands.
Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Vreugdenhil G; Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands.
van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
Hoop EO; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
Franken MG; Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Ryll B; Melanoma Patient Network Europe, Uppsala, Sweden.
Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Sleijfer S; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.
Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
van der Veldt AAM; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands. .; Department of Radiology & Nuclear Medicine, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Mar 25; Vol. 21 (1), pp. 323. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Immune Checkpoint Inhibitors/*administration & dosage
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Skin Neoplasms/*drug therapy
Withholding Treatment/*standards
Adult ; Consensus ; Drug Administration Schedule ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/standards ; Male ; Melanoma/immunology ; Multicenter Studies as Topic ; Practice Guidelines as Topic ; Prognosis ; Programmed Cell Death 1 Receptor/immunology ; Prospective Studies ; Quality of Life ; Response Evaluation Criteria in Solid Tumors ; Skin Neoplasms/immunology ; Standard of Care/standards ; Time Factors
Czasopismo naukowe
Tytuł :
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
Autorzy :
de Jong FC; Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Rutten VC; Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Zuiverloon TCM; Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Theodorescu D; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.; Departments of Surgery (Urology) and Pathology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 10; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
B7-H1 Antigen/*antagonists & inhibitors
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Urinary Bladder/*drug effects
Urinary Bladder Neoplasms/*drug therapy
Antibodies, Monoclonal, Humanized/immunology ; B7-H1 Antigen/immunology ; Drug Synergism ; Humans ; Immune Checkpoint Inhibitors/immunology ; Immune Checkpoint Inhibitors/therapeutic use ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Programmed Cell Death 1 Receptor/immunology ; Risk Factors ; Urinary Bladder/immunology ; Urinary Bladder/pathology ; Urinary Bladder Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Autorzy :
Pan C; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Yang H; Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310012, PR China; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310000, PR China.
Lu Y; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Hu S; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Wu Y; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
He Q; Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310058, PR China; Cancer Center of Zhejiang University, Hangzhou, 310058, PR China. Electronic address: .
Dong X; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310058, PR China; Cancer Center of Zhejiang University, Hangzhou, 310058, PR China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 05; Vol. 213, pp. 113170. Date of Electronic Publication: 2021 Jan 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
B7-H1 Antigen/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*pharmacology
Peptides/*pharmacology
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Small Molecule Libraries/*pharmacology
B7-H1 Antigen/metabolism ; Humans ; Immune Checkpoint Inhibitors/chemical synthesis ; Immune Checkpoint Inhibitors/chemistry ; Molecular Structure ; Peptides/chemical synthesis ; Peptides/chemistry ; Programmed Cell Death 1 Receptor/metabolism ; Protein Binding/drug effects ; Small Molecule Libraries/chemical synthesis ; Small Molecule Libraries/chemistry
Czasopismo naukowe
Tytuł :
Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
Autorzy :
Yang X; School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Cheng B; School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Xiao Y; Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, 430063, China.
Xue M; Tianjin Tiancheng Chemical Co., Ltd., Chemical Street, Binhai New District, Tianjin, 300480, China.
Liu T; School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Cao H; School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Chen J; School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 05; Vol. 213, pp. 113058. Date of Electronic Publication: 2020 Nov 30.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*chemical synthesis
B7-H1 Antigen/*immunology
Immune Checkpoint Inhibitors/*chemical synthesis
Programmed Cell Death 1 Receptor/*immunology
Stilbenes/*chemical synthesis
Tubulin/*metabolism
Tubulin Modulators/*chemical synthesis
Animals ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; B7-H1 Antigen/genetics ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Hep G2 Cells ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immunotherapy ; Mice, Inbred BALB C ; Molecular Docking Simulation ; Polymerization ; Programmed Cell Death 1 Receptor/genetics ; Protein Binding ; Stilbenes/pharmacology ; Structure-Activity Relationship ; Tubulin Modulators/metabolism
Czasopismo naukowe
Tytuł :
PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia.
Autorzy :
Meleveedu KS; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Chen D; Division of Hematopathology, Mayo Clinic Rochester, Mayo Clinic, Rochester, MN, USA.
Nadiminti K; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Sidiqi H; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Khan S; Division of Pediatric Hemato-Oncology, Mayo Clinic, Mayo Clinic, Rochester, MN, USA.
Alkhateeb H; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Shah MV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Patnaik M; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Hogan WJ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Begna K; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Litzow M; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Mar; Vol. 62 (3), pp. 764-767. Date of Electronic Publication: 2019 Oct 12.
Typ publikacji :
Letter
MeSH Terms :
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/genetics
Programmed Cell Death 1 Receptor*/genetics
B7-H1 Antigen/genetics ; Humans
Opinia redakcyjna
Tytuł :
Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.
Autorzy :
Lin G; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Zhang Y; Department of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College, Huai'an Second People's Hospital, Huai'an, Jiangsu 223002, P.R. China.
Yu L; Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200065, P.R. China.
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Pokaż więcej
Źródło :
Molecular medicine reports [Mol Med Rep] 2021 Mar; Vol. 23 (3). Date of Electronic Publication: 2021 Jan 26.
Typ publikacji :
Journal Article
MeSH Terms :
Adoptive Transfer*
Gene Silencing*
Leukemia, Myeloid, Acute/*immunology
Leukemia, Myeloid, Acute/*therapy
Programmed Cell Death 1 Receptor/*deficiency
Receptors, Chimeric Antigen/*immunology
Humans ; K562 Cells ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Programmed Cell Death 1 Receptor/immunology ; Receptors, Chimeric Antigen/genetics ; THP-1 Cells
Czasopismo naukowe
Tytuł :
Chemical characterization of a PD-1/PD-L1 inhibitory activity fraction of the ethanol extract from Gymnadenia conopsea .
Autorzy :
Lin PC; College of Pharmaceutical Sciences, Qinghai Nationalities University, Xining 810000, China.
Wang X; Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing 100191, China.
Zhong XJ; Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing 100191, China.
Zhou N; Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing 100191, China.
Wu L; College of Pharmaceutical Sciences, Qinghai Nationalities University, Xining 810000, China.
Li JJ; Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing 100191, China.
Hu YT; The 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, Nanchang 330047 China.
Shang XY; Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing 100191, China.
Pokaż więcej
Źródło :
Journal of Asian natural products research [J Asian Nat Prod Res] 2021 Mar; Vol. 23 (3), pp. 235-249. Date of Electronic Publication: 2020 Dec 02.
Typ publikacji :
Journal Article
MeSH Terms :
Ethanol*
Programmed Cell Death 1 Receptor*
B7-H1 Antigen ; Chromatography, High Pressure Liquid ; Molecular Structure
Czasopismo naukowe
Tytuł :
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
Autorzy :
Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands.
Fogli S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Cucchiara F; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Capuano A; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Scavone C; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Jenster GW; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: .
Pokaż więcej
Źródło :
Biochimica et biophysica acta. Reviews on cancer [Biochim Biophys Acta Rev Cancer] 2021 Jan; Vol. 1875 (1), pp. 188463. Date of Electronic Publication: 2020 Nov 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
B7-H1 Antigen/*antagonists & inhibitors
Extracellular Vesicles/*genetics
Neoplasms/*therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen/blood ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Neoplasms/blood ; Neoplasms/genetics ; Neoplasms/immunology ; Programmed Cell Death 1 Receptor/blood ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/immunology
Czasopismo naukowe
Tytuł :
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
Autorzy :
Roither B; Institute of Biosimulation and Bioinformatics, Medical University of Vienna, Spitalgasse 23/88.04.510, 1090, Vienna, Austria.
Oostenbrink C; Institute of Molecular Modeling and Simulation, University of Natural Resources and Life Science, Vienna, Muthgasse 18, 1190, Vienna, Austria.
Schreiner W; Institute of Biosimulation and Bioinformatics, Medical University of Vienna, Spitalgasse 23/88.04.510, 1090, Vienna, Austria. .
Pokaż więcej
Źródło :
BMC bioinformatics [BMC Bioinformatics] 2020 Dec 14; Vol. 21 (Suppl 17), pp. 557. Date of Electronic Publication: 2020 Dec 14.
Typ publikacji :
Journal Article
MeSH Terms :
Molecular Dynamics Simulation*
B7-H1 Antigen/*chemistry
Nivolumab/*immunology
Programmed Cell Death 1 Receptor/*chemistry
Antibodies, Monoclonal/immunology ; B7-H1 Antigen/metabolism ; Cluster Analysis ; Humans ; Hydrogen Bonding ; Ligands ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Protein Binding ; Protein Domains
Czasopismo naukowe
Tytuł :
N-glycosylation of PD-1 promotes binding of camrelizumab.
Autorzy :
Liu K; Faculty of Health Sciences, University of Macau, Macau SAR, China.; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
Tan S; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Jin W; College of Life Science, Research Center for Glycobiology and Glycotechnology, College of Food Science and Technology, Northwest University, Xi'an, China.
Guan J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Wang Q; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Sun H; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Qi J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Yan J; CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Chai Y; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Wang Z; College of Life Science, Research Center for Glycobiology and Glycotechnology, College of Food Science and Technology, Northwest University, Xi'an, China.
Deng C; Faculty of Health Sciences, University of Macau, Macau SAR, China.
Gao GF; Faculty of Health Sciences, University of Macau, Macau SAR, China.; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
Pokaż więcej
Źródło :
EMBO reports [EMBO Rep] 2020 Dec 03; Vol. 21 (12), pp. e51444. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Escherichia coli*/metabolism
Programmed Cell Death 1 Receptor*/genetics
Programmed Cell Death 1 Receptor*/metabolism
Antibodies, Monoclonal, Humanized ; Glycosylation ; Humans
Czasopismo naukowe
Tytuł :
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
Autorzy :
Zhang F; Beijing Advanced Innovation Center for Genomics, School of Life Sciences, BIOPIC, Peking University, Beijing, 100871, China.; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Bai H; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Gao R; Beijing Advanced Innovation Center for Genomics, School of Life Sciences, BIOPIC, Peking University, Beijing, 100871, China.; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Fei K; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Duan J; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Zhang Z; Beijing Advanced Innovation Center for Genomics, School of Life Sciences, BIOPIC, Peking University, Beijing, 100871, China.; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Wang J; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. .
Hu X; Beijing Advanced Innovation Center for Genomics, School of Life Sciences, BIOPIC, Peking University, Beijing, 100871, China. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Dec; Vol. 69 (12), pp. 2599-2611. Date of Electronic Publication: 2020 Jun 26.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocyte Subsets/*drug effects
Aged ; Antineoplastic Agents, Immunological/pharmacology ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/immunology ; Clinical Trials, Phase III as Topic ; Disease Progression ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lung/diagnostic imaging ; Lung/pathology ; Lung Neoplasms/blood ; Lung Neoplasms/diagnosis ; Lung Neoplasms/immunology ; Male ; Middle Aged ; Multicenter Studies as Topic ; Nivolumab/pharmacology ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; RNA-Seq ; Randomized Controlled Trials as Topic ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; Single-Cell Analysis ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies